Recursion Pharmaceuticals Inc
NASDAQ:RXRX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.7
15.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Additional Paid In Capital
Recursion Pharmaceuticals Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
Additional Paid In Capital
$1.4B
|
CAGR 3-Years
481%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$21.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$6.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$12.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
24%
|
CAGR 10-Years
18%
|
|
Recursion Pharmaceuticals Inc
Glance View
In the bustling landscape of biotech innovation, Recursion Pharmaceuticals Inc. carves a distinctive niche by marrying the worlds of biology and advanced computational techniques. Founded in 2013, this Salt Lake City-based company embarked on a mission to decode the complex tapestry of disease biology through the lens of data science and machine learning. Recursion's approach centers around its unique platform that integrates automated experimental biology with artificial intelligence to map and navigate the intricate pathways of human cellular biology. By harnessing volumes of data from high-throughput biological experiments, they aim to unearth novel insights into a multitude of diseases, particularly those that have historically evaded effective therapeutic intervention. At the heart of Recursion's business model is its ability to discover potential drug candidates rapidly and efficiently, turning traditional pharmaceutical development on its head. The company generates revenue through strategic partnerships with pharmaceutical giants, leveraging its platform to accelerate drug discovery and development processes. Collaborations often involve sharing the risk and reward of drug discovery, with Recursion providing the technological backbone to sift through vast datasets and identify promising therapeutic compounds. Additionally, Recursion invests in its pipeline of proprietary drug candidates, targeting rare genetic diseases and areas of significant unmet medical need. By aligning cutting-edge technology with the complexities of human biology, Recursion Pharmaceuticals positions itself at the forefront of transforming how diseases are understood and how new treatments are developed.
See Also
What is Recursion Pharmaceuticals Inc's Additional Paid In Capital?
Additional Paid In Capital
1.4B
USD
Based on the financial report for Dec 31, 2023, Recursion Pharmaceuticals Inc's Additional Paid In Capital amounts to 1.4B USD.
What is Recursion Pharmaceuticals Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
481%
Over the last year, the Additional Paid In Capital growth was 27%. The average annual Additional Paid In Capital growth rates for Recursion Pharmaceuticals Inc have been 481% over the past three years .
You don't have any saved screeners yet
